Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir
- 1 October 2005
- journal article
- Published by Elsevier BV in Antiviral Research
- Vol. 68 (1), 27-35
- https://doi.org/10.1016/j.antiviral.2005.07.003
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Small-Molecule Inhibition of Human Immunodeficiency Virus Type 1 Replication by Specific Targeting of the Final Step of Virion MaturationJournal of Virology, 2004
- Selection of High-Level Resistance to Human Immunodeficiency Virus Type 1 Protease InhibitorsAntimicrobial Agents and Chemotherapy, 2003
- Changes in Human Immunodeficiency Virus Type 1 Gag at Positions L449 and P453 Are Linked to I50V Protease Mutants In Vivo and Cause Reduction of Sensitivity to Amprenavir and Improved Viral Fitness In VitroJournal of Virology, 2002
- Impact of HIV Type 1 Drug Resistance Mutations and Phenotypic Resistance Profile on Virologic Response to Salvage TherapyAIDS Research and Human Retroviruses, 2001
- Phenotypic Cross-Resistance to Nelfinavir: The Role of Prior Antiretroviral Therapy and the Number of Mutations in the Protease GeneAIDS Research and Human Retroviruses, 2001
- Polymorphism of HIV Type 1 Gag p7/p1 and p1/p6 Cleavage Sites: Clinical Significance and Implications for Resistance to Protease InhibitorsAIDS Research and Human Retroviruses, 2000
- HIV Type 1 Protease Cleavage Site Mutations and Viral Fitness: Implications for Drug Susceptibility Phenotyping AssaysAIDS Research and Human Retroviruses, 2000
- HIV-1 evolution under pressure of protease inhibitors: Climbing the stairs of viral fitnessJournal of Biomedical Science, 1999
- Impact of drug resistance mutations on virologic response to salvage therapyAIDS, 1999
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995